Linaprazan glurate

Linaprazan glurate (X842) is an orally atcive prodrug of Linaprazan (HY-100412) with a potent and prolonged inhibitory effect on gastric acid secretion. Linaprazan glurate is rapidly transformed by enzymatic cleavage into its active metabolite, linaprazan. Linaprazan glurate is a potassium-competitive acid blocker. Linaprazan glurate selectively inhibites acid formation from gastric H⁺/K⁺-ATPase in a potassium-dependent manner (IC50 = 436.2 nM) . Linaprazan glurate can be used for the studies of erosive esophagitis (EE) [1][2].

Product Specifications

CAS Number

[1228559-81-6]

Product Name Alternative

X842

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Drug Intermediate; Proton Pump

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/linaprazan-glurate.html

Concentration

10mM

Purity

99.65

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(CCCC(OCCNC(C1=CN2C(C)=C(C)N=C2C(NCC3=C(C)C=CC=C3C)=C1)=O)=O)O

Molecular Formula

C26H32N4O5

Molecular Weight

480.56

Precautions

H302, H315, H319

References & Citations

[1]Zhang X, et al. Absorption, distribution, metabolism and excretion of linaprazan glurate in rats. J Pharm Biomed Anal. 2024 May 15;242:116012. |[2]Lu M, et al. Pharmacological characterization of linaprazan glurate (X842), a novel potassium-competitive acid blocker, in vitro and in vivo. Front Pharmacol. 2025 Sep 5;16:1636523.